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Available online 8 May 2012Analysis of cryopreserved peripheral mononuclear cells (PBMC) is important for evaluating new
vaccines in immune based therapies and in pathogenesis studies. To ensure comparable assay
results from different laboratories and points of time, collaborative research in multicenter trials
needs reliable and reproducible cryopreservation protocols that maintain cell viability and
functionality. Current cryomedia consist largely of fetal bovine serum (FBS), a natural mix of
growth factors, cytokines, and undefined compounds. Standardized procedures are not possible, as
FBS can affect the antigen-specific T-cell response, the most important parameter in functionality
assays. Also, worldwide sample exchange is complicated by the strict import restrictions on FBS,
because of transfection risk.
After establishing a serum-free cryopreservation protocol that maintains cell viability,
recovery and antigen-specific T-cell response of PBMC comparably to FBS-based cryomedia
(Germann et al., 2011), the aim of this study was the complete avoidance of animal proteins
and products in combination with efficient cryopreservation.
As long-term stability of the cryopreservation process is crucial for retrospective evaluation of
samples at different points of time, PBMC were analyzed after storage for maximal four weeks
and again after approximately six months.
The cryopreservation efficiency of the protein-free and fully chemically defined cryomedium was
comparable to FBS-medium after storage for fewweeks and several months. Directly after thawing,
this medium yielded viabilities over 97% and recovery values over 84%. Also, the specific T-cell
functionality was preserved. Additionally, short-term and six month cryopreservation gave
comparable results. The fully chemically defined medium presented here will increase standard-
ization and reproducibility of analysis in multicenter-studies or in retrospective evaluation.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. Keywords:
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Peripheral blood mononuclear cells (PBMC) are important
for the development of immune based therapies and clinical
vaccine studies. An increasing number of investigations focus
on diseases affecting cellular immunity, including HIV (Torresi
et al., 2004; Mlotshwa et al., 2010), tuberculosis (Sester et al.,
2010) and cancer (Gilboa, 2004), using PBMC for assay readout.
Changes in the antigen-specific T-cell response indicate the
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antibody synthesis. However, the time slot for reliable results
after PBMC isolation is quite narrow (Bull et al., 2007). This
makes comparison of results difficult between laboratories and,
following Luyet and Hodapp, 1938, new cryopreservation
methods have been continuously developed. At temperatures
below −130 °C, metabolic activity is significantly reduced and
cells can theoretically be kept for long periodswithout effects on
properties and function (Hunt, 2007). Effective and reproducible
cryopreservation protocols for PBMC enable the setup of large
sample repositories, allowing retrospective monitoring in
pathogenesis studies and inter-laboratory controls of assay
outcomes. Today, most active phase II/III vaccine studies already
bank cells from all participants to allow repeated analysis of the
immunological response at different points of time.
Suboptimal cryopreservation results in a significant decrease
of cell viability and number, and may also cause alterations of
the cellular phenotype and a reduction of the immunogenic
response to specific antigens (Costantini et al., 2003). Therefore,
the use of cryopreserved PBMC in functional assays has to be
validated and cryopreservation protocols have to be adapted to
guarantee reliable and reproducible results. A wide range of
studies have already been performed, analyzing the effects of
freezing and thawing on PBMC. Most results showed only
minimal effects on the viability of cells (Birkeland, 1980; Sobota
et al., 1997; Hayes et al., 2002), with a clear correlation of
viability and T-cell function in lymphocyte assays (Reimann et
al., 2000; Weinberg et al., 2000). However, preservation of
antigen-specific T-cell response is under permanent critical
discussion. Some studies found no significant difference
between fresh and frozen cell responses to recall antigens
(Kreher et al., 2003; Maecker et al., 2005; Disis et al., 2006),
whereas others reported an increase in frozen samples
(Weinberg et al., 1998) or reduced function in lymphocyte
assays against HIV p24 and CMV antigens, as well as against
mitogens (Costantini et al., 2003;Miniscalco et al., 2003; Owen
et al., 2007) after cryopreservation. Further studies on antigen-
specific T-cell response are necessary to evaluate these results.
Typically, cryomedia consisting of fetal bovine serum
supplemented with 10% dimethyl sulfoxide (DMSO) are used
to protect cells against damage during cryopreservation, like
solution effects, by influencing the water content of cells.
However, DMSO is also toxic and its addition and removal is a
complex process associated with potentially detrimental
osmotic shock to the cells (Luciano et al., 2009). So the
reduction of the DMSO concentration is necessary.
Also, the use of fetal bovine serum (FBS) is under constant
discussion by regulatory authorities (Korhonen, 2007), as
there is the risk of transmitting potentially infectious agents,
for example the bovine spongiform encephalopathy virus
(Will et al., 1996; Bradley, 2004), to the cell samples. Many
infectious agents like bacteria and viruses are even capable of
surviving at the low temperatures (−160 °C) that are
routinely used for the storage of cell stocks (Bielanski et al.,
2003; Hubalek, 2003).
FBS is a natural and undefinedmixture of different growth
factors and nutrients, impeding a standardized and repro-
ducible cell preparation and assay evaluation. The Cancer
Vaccine Consortium of the Sabin Vaccine Institute (CVC/SVI)
reported that serum choice among their participants was
responsible for suboptimal performance in one of theirinternational Enzyme Linked Immuno Spot (ELISpot) profi-
ciency panels (Janetzki et al., 2008). Obtaining reliable results
in functional assays requires intensive and time-consuming
pretesting of FBS to identify batches with low background
reactivity and optimal antigen-response. Also, strict import
restrictions on FBS prevent an unlimited exchange of frozen
samples.
Ideally, media should be free of all undefined additives and
possible sources of contamination, which means avoiding all
animal-derived products. Our aim in this studywas to compare
different approaches for achieving xeno-free or chemically
defined, standardized and reproducible cryopreservation pro-
tocols. We tested: two completely protein-free and fully
chemically defined media, already resulting in efficient cryo-
preservation of different adult stem cell types (Zeisberger et al.,
2011); a medium containing bovine serum albumin (BSA)
fraction V, a defined and widely accepted substitute for FBS
(Germann et al., 2011), and a medium containing human
serum albumin (HSA) as xeno-free alternative (Liu et al., 2010).
Several serum-free cryopreservation media and methods have
already been developed and distributed on themarket as GMP-
compliant or -amenable products (Grein et al., 2010; Holm et
al., 2010; Liu et al., 2010), but none of them are completely
protein-free. The protein-freemedia, used in the present study,
were specifically designed to compensate for the damaging
effects of low temperatures under xeno-free and chemically
defined conditions (Gonzalez Hernandez and Fischer, 2007).
The immediate effects of freezing and thawing on cell
membranes and organelles, e.g. intracellular ice formation
and recrystallization, are mostly understood but the long-
term consequences are still quite unknown (Vysekantsev et
al., 2005). The ability to store samples for periods of months or
years without loss of viability and functionality is crucial for
many clinical and research studies. Blood samples collected
during the evolution of a disease help to understand the
development of different viral variants and disease patterns.
Another aim of this study was to compare the effects of
short- and long-term cryopreservation in the different serum-
and protein-free media on the viability and functionality of the
PBMC in context of the HIV Specimen Cryorepository (hsc;
www.hsc-csf.org). Samples were analyzed after someweeks of
storage and again after several months. Accurate quantification
of the cellular immune response is important in such studies
because the T-cell functionality is a key issue in vaccine
research, as it plays an essential role in the control of viral
replication (Borrowet al., 1994; Rosenberg et al., 1997; Altfeld et
al., 2001; McMichael and Rowland-Jones, 2001). To guarantee
an exact evaluation of the results, automated trypan blue
exclusion and interferon-γ ELISpot (Enzyme Linked Immuno
Spot Technique)were used formeasuring the viability, recovery,
and functionality of PBMC after cryopreservation.
In summary, we investigated the effects of short- and
long-term storage in serum- or even completely protein-free
cryopreservation media on the viability and functionality of
PBMC, also with regard to a possible reduction of the necessary
DMSO concentration. As 6 month cryopreservation is quite
short for long-term results, it is planned to validate the results
in this paper with already frozen samples after storage for
longer than one year. However, the results shown in this paper
give enough evidence to be taken into account for upcoming
studies.
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2.1. Sample collection, processing and handling
Citrated blood samples of 13 healthy, CMV seropositive
donorswere obtained from the blooddonor center Saarbruecken
with informed consent. Peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifugation over
lymphocyte separation medium (PAA, Cölbe). The buffy coat
layers were collected and washed with PBS (Gibco, Karlsruhe).
Contaminating red blood cells were lysed using Pharm Lyse (BD,
Heidelberg) by incubating 2×108 cells in 20 ml of 1/10 diluted
Pharm Lyse in distilled water (B. Braun, Melsungen) for 30 min
in the dark. Reaction was stopped by adding 30 ml of PBS with
1% pretested FBS (PAA, Cölbe).2.2. Media used for cryopreservation
Five different cryomedia were used for freezing freshly
isolated PBMC:
a) GHRC-CryoMedium I contained 12.5% BSA fraction V in
RPMI 1640 (PAA, Cölbe) supplemented with 10% DMSO,
as already described (Germann et al., 2011).
b) GHRC-CryoMedium III consisted of 12.5% human serum in
RPMI 1640 (PAA, Cölbe) with a final DMSO concentration
of 10% (a xeno-free alternative).
c) IBMT-Medium Iwas a fully chemically defined and protein-
free cryomedium, based on 1% Poloxamer188 that is ready
to use, containing 10% DMSO (Fischer Procryotect, Zurich,
licensed by Fraunhofer IBMT, St. Ingbert).
d) IBMT-Medium II was as c) but containing 5% DMSO.
e) The control medium was pretested, heat-inactivated FBS
(PAA, Cölbe) supplemented with 10% DMSO (Sigma-Aldrich,
Taufkirchen).
The GHRC-CryoMedia consisted of two solutions. Solution
A contained no DMSO, solution B was supplemented with
20% DMSO (Sigma-Aldrich, Taufkirchen). All cryomedia were
freshly prepared and chilled at 4 °C.2.3. Cryopreservation of PBMC
Density gradient-isolated PBMC were resuspended at a
concentration of 23×106 cells/ml in solution A of the GHRC-
CryoMedium I or III. An equal amount of solution B was
added dropwise resulting in a final DMSO-concentration of
10% and a PBMC-concentration of 11.5×106 cells/ml. With
the protein-free and the FBS-based cryomedia, PBMC were
directly resuspended in the medium at a concentration of
11.5×106 cells/ml.
1 ml aliquots of cell suspension were immediately trans-
ferred to precooled (−20 °C) cryovials (Sarstedt, Nürnbrecht),
placed into a freezing isopropanol container (VWR, Darmstadt;
cooling rate of 1 °C/min) for freezing and stored at −80 °C
overnight. Afterwards, samples were transferred to the gas
phase of a liquid nitrogen tank and stored for no more than
4 weeks or for, on average, 6 months, comparing the short- and
long-term effects of the cryopreservation protocol.2.4. Thawing PBMC
For thawing, IMDM medium (Gibco, Karlsruhe) containing
L-glutamine, 25 mM HEPES buffer, and 3.024 g/l sodium
bicarbonate was used, supplemented with 10% of the same
pretested, heat-inactivated FBS (PAA, Cölbe) as used for
cryopreservation and 1 mML-glutamine (Gibco, Karlsruhe).
The cryovialswere directly transferred from the liquid nitrogen
tank to a 37 °Cwater bath and samples were thawed until only
little ice remained. Afterwards, 1 ml of the thawing medium
was slowly added to the PBMC suspension and the sample
was transferred to a 50 ml polypropylene tube (Sarstedt,
Nürnbrecht) containing 9 ml prewarmed thawing medium.
The tubes were centrifuged with 400 g for 5 min. The PBMC
were resuspended in 10 ml thawing medium and placed in a
cell incubator (5% CO2, 37 °C) overnight with a loose cap.
2.5. Determination of PBMC viability and recovery
The efficiency of the cryopreservation protocolwas evaluated
after short- (2.6±1.1 weeks) and long-term storage (5.4±
1.6 months) of the PBMC in the gas phase of a liquid nitrogen
tank. 3 samples per cryomedium and donor were thawed and
cell recovery and viability were measured directly and after
overnight rest using trypan blue exclusion by ViCell (Beckman
Coulter, Krefeld). Each sample was measured three times.
Cell recovery and cell viability were calculated in the
following way:
Recovery %ð Þ directly after thawing;0 hð Þ :
%recovery ¼ number of viable PBMC after thawing
 100=number of frozen viable PBMC
Recovery %ð Þ after overnight rest;24hð Þ :
%recovery ¼ number of viable PBMC after overnight rest
 100=number of frozen viable PBMC
–number of viable PBMC removed for
measurement at 0 h

%viability ¼ number of viable PBMC
 100=number of total PBMC
2.6. IFN-γ ELISpot assay
PBMC were assayed for IFN-γ production in the presence of
CMV (cytomegalovirus) pp65 peptide pool (BD Bioscience,
Heidelberg), CEF peptide pool (cytomegalovirus, Epstein–Barr
virus, and influenza virus, CTL, Bonn), PHA (phytohemagglutinin,
Sigma-Aldrich, Taufkirchen) andmedia containing 0.4%DMSO in
triplicates. Responsiveness of donors against the CEF peptide
pool was guaranteed, as the chosen pool covers determinants
restricted by 11 HLA alleles: A1, A2, A3, A11, A24, A68, B7, B8,
B27, B35, and B44.Most Caucasian individual express at least one
of these alleles and the 23 peptides selected cover CD8 cell
epitopes in most Caucasians (Currier et al., 2002).
96well plate anti-h-IFN-γmAb 1-D1k precoated (Mabtech,
Hamburg)werewashed four timeswith PBS (Gibco, Karlsruhe)
and blocked with IMDM containing 10% of the same
pretested FBS (PAA, Cölbe) as used for cryopreservation and
1 mML-glutamine for 30 min. Cryopreserved PBMC were
thawed as described above and used the next day. Approxi-
mately 2×105 PBMC were added to the CEF, CMV and
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peptides, CMV peptides and PHA were added to a final
concentration of 128 μg/ml, 483 μg/ml and 8 μg/ml, respectively.
The plates were incubated at 37 °C, 5% CO2 for 20–22 h. After
washing the plates five times with PBS the production of IFN-γ
by T-cells was measured by addition of 1/200 diluted HRP-
labeled detection mAb 7-B6-1 (Mabtech, Hamburg) in sterile
filtered PBS containing 0.5% pre-tested FBS. After incubation, the
plates were washed five times with PBS. The spots were
developed using Nova Red Substrate Kit (Vector, CA). Spot
development was stopped after approximately 1–2 min by
extensively washing with distilled water. The spots were
evaluated with the Immunospot Analyser (CTL, Bonn). The
results were expressed as spot forming cells (SFC per million
PBMC).
2.7. Statistical analysis
For analysis of cell recovery and viability, results are
expressed as mean±standard deviation. As a Gaussian distri-
bution cannot be assumed using different blood donors,
comparisons of the different serum-free cryomedia in relation
to FBS-based medium were validated using the Wilcoxon
Signed-Rank Test, a non-parametric statistical hypothesis test.
The PBMC recovery and viability of the tested serum-free
cryomedia was considered to be statistically significant equal
or better than the FBS-based medium with a p-valueb0.05.
3. Results
3.1. PBMC recovery and viability after short- and long-term
cryopreservation
PBMC from healthy, CMV seropositive donors were
isolated and cryopreserved in 5 different cryomedia: serum-
free GHRC-CryoMedium I, based on BSA fraction V, containing
10%DMSO; xeno-freeGHRC-CryoMedium III, based onHSAwith
10% DMSO; protein-free, fully chemically defined cryomedia
containing 10% (IBMT-Medium I) or 5% DMSO (IBMT-Medium
II) and heat-inactivated, pretested FBS supplemented with 10%
DMSO. Samples were thawed and analyzed after maximal
4 weeks and after approximately 6 months of storage, regarding
cell recovery (Fig. 1A and B) and cell viability (Fig. 1C and D)
directly after thawing (0 h) and after overnight rest (24 h).
The median recoveries of the samples stored for up to
4 weeks were directly after thawing (Fig. 1A) between 84.84±
8.08% (protein-free medium with 5% DMSO) and 88.62±
10.32% (FBSwith 10%DMSO). The remaining PBMCwere rested
overnight and cell recovery (Fig. 1A) and viability (Fig. 1C)were
measured again. After overnight rest, the recovery was reduced
in all samples, independent of cryomedium used and duration
of storage (Fig. 1A and B). The recovery values for the short-
term stored samples were lowest for the protein-free cryome-
dium with 5% DMSO (69.00±6.66%) and highest using BSA
(77.40±4.97%).
Directly after thawing of the PBMC after short-term storage,
the cell viability was high in all samples with values over 96%,
independent of the cryomedium. Viability decreased margin-
ally in all samples after overnight rest (Fig. 1C) with results
between 91.05±1.90% (protein-free medium with 5% DMSO)
and 94.75±1.59% (FBS with 10% DMSO).After long-term storage, no significant differences in the
recovery and viability could be detected (Fig. 1B and D),
compared to the short-term results. The recovery results,
normalized to the short-term performance, show amean value
of 1.00±0.05 directly after thawing and 0.97±0.05 24 h later.
Additionally, the viability of all samples, both directly after
thawing (1.00±0.00) and after overnight rest (1.01±0.01),
was identical to the short-term results.
Cryopreservation in all serum-free cryomedia gave high
viability and recovery values with maximum results for both
the BSA-basedmedium and the protein-free mediumwith 10%
DMSO. Cells were long-term stable in all of the cryomedia.
3.2. Characterization of T-cell response in IFN-γ ELISpot assay
The maintenance of T-cell responses during cryopreser-
vation is most important. Therefore, PBMC cryopreserved in
the five different media were tested in IFN-γ ELISpot using
CMV and CEF peptide pools as immunogenic antigens after
up to 4 weeks and after, on the average, 6 months of storage
(Table 1).
To classify positive responses, the average number of spot
forming cells (SFC) per 106 PBMC was determined; three
replicates were used for this calculation. Following “Stan-
dardization and Validation Issues of ELISpot Assay” (Janetzki
et al., 2005) we used the definition of responder R>4D and
R>55 [R is the reagent SFC/106 PBMC, D corresponding to
SFC for diluent (background)].
Using the definition above, after short- and long-term
storage 12/13 PBMC samples were responsive to the CMV
and 9/13 to the CEF (Table 1) peptide pool, independent of
the cryomedium. Also, with 0 to 12 spot-forming cells per
106 PBMC, the background was very low, independent of
cryomedium used and storage duration (data not shown).
The results indicated, that after cryopreservation using
the HSA-based medium, the specific reactivity mainly against
CMV antigens was reduced in several samples (e.g. donors #1
and #5, Table 1), whereas using the protein-free medium
with only 5% DMSO, the response against both stimulants
was decreased, independent of storage duration (e.g. donors
#6 and #12, Table 1). In contrast, the response to antigen
stimulation after cryopreservation using BSA-based medium
and protein-free medium supplemented with 10% DMSO was
comparable to the FBS-based medium. In summary, these
twomedia represent alternatives to serum-containing media.
For evaluating the effects of long-term storage on the
functionality of frozen PBMC, the antigen-specific release of
IFN-γ was analyzed again after storage of approximately
6 months. The INF-γ release in samples #1 to #6 after
stimulation with both peptide pools seemed to be slightly
decreased, mainly after cryopreservation in the HSA-based
medium with 10% DMSO and the protein-free medium with
5% DMSO, but not in the remaining samples. Nevertheless,
storage of PBMC for several months in the gas phase of liquid
nitrogen seems not to have an adverse effect on the specific
functionality of PBMC.
In summary, these results show, that cell viability, recovery
and T-cell functionality can be maintained for at least several
months of cryogenic storage, using the cryopreservation pro-
tocols described here. Compared to FBS, the HSA-based and the
protein-free media (5% DMSO) showed slightly poorer results,
Fig. 1. Comparison of PBMC recovery (A, B) and viability (C, D) after short- (2.6±1.1 weeks, A, C) and long-term storage (5.4±1.6 months, B, D). Samples were
analyzed directly after thawing (0 h) and after overnight rest (24 h). The mean value of 13 test series with standard deviation after cryopreservation of PBMC in
GHRC-CryoMedium I (BSA with 10% DMSO), III (HSA with 10% DMSO), IBMT-Medium I and II (protein-free medium with 10% and 5% DMSO) and 90% FBS
supplemented with 10% DMSO were presented after short-term storage (A, C). All single values after long-term storage were normalized to the corresponding
short-term results (B, D) and are shown as box-and-whisker-plot. *Statistically equal to FBS (p≤0.05).
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IBMT-Medium I results were comparable to those of the FBS-
based cryomedium, representing serum- or even protein-free
alternatives.4. Discussion
High-quality and reproducible cryopreservation is extreme-
ly important and demanding. It enables: standardized analysis
of in-field studies; transport of samples to competence centers;
simultaneous assessment of samples reduces inter-assay
variability; and retrospective analysis.
However, cryopreservation can have tremendous effects on
the recovery and functionality of cells. The high concentrations
of salts and other solutes, induced by ice formation, cause
damage through dehydration (Lovelock, 1953a; Mazur et al.,
1972), cell shrinkage (Meryman, 1970; Steponkus et al., 1983),and electric induced membrane breakdown (Steponkus et al.,
1985; Zimmermann and Neil, 1996).
Therefore, a precise and rigorous appreciation of the
impact of cryopreservation is required for interpreting the
results of studies based on T-cell functionality. However, the
outcomes of investigations concerning the effects of cryo-
preservation on the viability and functionality of T-cells are
quite inconsistent. Several previous studies have indicated an
adequate maintenance of function of cryopreserved PBMC
compared to cells in whole blood, measured using: prolifera-
tion assays (Allsopp et al., 1998; Jeurink et al., 2008; Weinberg
et al., 2009); cytokine production (Kreher et al., 2003;
Kvarnstrom et al., 2004; Kierstead et al., 2007; Nilsson et al.,
2008); apoptosis (Riccio et al., 2002), and HLA tetramer
staining (Appay et al., 2006), while others suggest a loss of
function (Owen et al., 2007). Therefore, standardized cryo-
preservation protocols and reliable PBMC-based assays such as
enzyme-linked immunospot (ELISpot) assay and others, e.g.
Table 1
ELISpot response of 13 donors stimulated with CMV and CEF peptide pool after cryopreservation for up to four weeks and for approximately 6 months. Donor #3
was not responsive to the CMV- and CEF-stimulation, donors #1, #2, and #11 not to the CEF-stimulation. Values shown are averaged numbers with standard
deviation of spot forming cells (SFC) per 106 PBMC from three replicate wells.
CMV 2.6±1.1 weeks 5.4±1.6 months
Donor BSA+10% Da HSA+10% Db PF+5% Dc PF+10% Dd FBS+10% De BSA+10% Da HSA+10% Db PF+5% Dc PF+10% Dd FBS+10% De
#1 1662±419 798±100 802±127 1703±413 1315±170 1460±85 507±56 470±40 1065±133 1160±115
#2 655±56 352±57 593±25 827±47 843±116 570±66 233±36 298±52 685±208 533±111
#4 397±88 263±35 305±65 113±43 300±119 275±15 160±25 105±22 208±81 183±24
#5 2662±237 1920±195 2663±75 2203±50 2477±124 2178±206 1300±17 1763±169 2165±48 2250±178
#6 2192±132 2168±110 1302±41 2007±128 2163±213 1742±71 1435±91 1138±126 1848±43 1693±68
#7 167±46 167±19 93±16 153±18 175±41 183±39 137±58 117±18 183±55 218±88
#8 2430±418 3108±181 3533±211 3290±196 2163±213 3427±165 3630±25 3672±165 3220±226 2862±425
#9 472±35 113±23 162±33 492±205 482±141 623±236 177±20 143±33 440±195 482±134
#10 1235±41 995±289 733±153 773±109 1167±63 1218±48 1125±118 645±105 1218±68 1295±64
#11 2827±224 2312±236 2315±160 2528±89 2620±247 3542±75 3305±59 3363±176 3497±101 3463±29
#12 2472±68 2365±109 1898±243 2160±161 2405±44 2643±28 2408±81 2090±38 2205±65 2063±261
#13 2407±151 1775±286 1615±57 2127±116 2290±212 2443±90 2545±354 1700±278 2373±511 2030±234
CEF 2.6±1.1 weeks 5.4±1.6 months
Donor BSA+10% Da HSA+10% Db PF+5% Dc PF+10% Dd FBS+10% De BSA+10% Da HSA+10% Db PF+5% Dc PF+10% Dd FBS+10% De
#4 912±115 1032±109 960±214 300±75 853±16 955±115 533±117 288±124 663±88 670±137
#5 1975±26 2015±170 1968±73 1690±126 1988±221 1652±64 1740±78 1133±107 1910±144 1665±69
#6 1250±71 1402±120 495±40 1115±139 1323±90 885±95 912±88 440±59 970±142 892±91
#7 838±59 978±68 455±35 743±96 740±52 1110±105 1132±137 1263±129 1543±123 1368±144
#8 2807±135 2965±133 2185±60 2760±59 3145±36 2613±157 2178±170 1795±84 2395±124 2178±196
#9 550±66 385±75 190±70 532±93 495±112 688±10 423±90 120±72 495±56 665±54
#10 317±63 285±22 158±12 227±13 423±48 298±38 208±80 250±184 260±71 268±83
#12 2600±20 2590±48 1788±162 2277±123 2507±26 2645±138 2582±65 2073±111 2397±42 2213±201
#13 2740±83 2558±89 2268±121 2612±59 2582±61 3040±212 3123±161 2337±146 2795±218 2687±235
a GHRC-CryoMedium I (BSA with 10% DMSO).
b GHRC-CryoMedium III (HSA with 10% DMSO).
c IBMT-Medium II (protein-free medium with 5% DMSO).
d IBMT-Medium I (protein-free medium with 10% DMSO).
e 90% FBS with 10% DMSO.
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crucial for selecting candidates for large scale efficacy testing.
Also, some researchers state that it is thawing and the
potential overnight rest rather than the processing and
cryopreservation that have detrimental effects on PBMC
(Kreher et al., 2003; Kierstead et al., 2007).
The aim of this study was to increase standardization and
reproducibility of cryopreservation by developing strategies for
complete avoidance of animal products. Here we investigated
the possibility of substituting the standard, serum-based
cryopreservation with a serum-free protocol using serum
alternatives (BSA fraction V and HSA), towards a protein-free,
chemically defined cryomedium. Pretested serumwas used for
thawing and ELISpot analysis of all samples, as recommended
by standard protocols.
DMSO is extensively used as a cryoprotectant because of
its high membrane permeability (Wang et al., 2007).
Intracellular DMSO replaces thewater shell inmacromolecules,
so that cells are able to survive intracellular ice crystallization
(Lovelock, 1953b). However, high concentrations of permeat-
ing solutes can result in extensive initial dehydration followed
by rehydration (Woods et al., 2004). The resultant cellular
shrinking and swelling can cause damage and even cell death
(Mazur and Schneider, 1986). Therefore, the aim of this study
also was to investigate the effects of a reduced DMSO
concentration on the recovery and functionality of PBMC. The
protein-free medium was used with a DMSO concentration of
10% and 5%. However, the viability and recovery values as wellas the specific T cell reactivity against CEF and CMV peptides
were slightly decreasedwith the reduced DMSO concentration.
Thus, a simple reduction of DMSO seems not to be possible, so
next steps should involve extracellular cryoprotectants like
trehalose or hydroxyethyl starch (HES) (Ehrhart et al., 2009).
Sample quality has to be guaranteed during long-term
storage of cells for retrospective analysis. Previous studies
have already demonstrated that T-cell subsets do not appear to
be significantly altered by cryopreservation or storage for up to
12 months (Ludgate et al., 1983; Glassman and Christopher,
1984; Prince and Lee, 1986). Our results also show that there
were no significant differences in viability, recovery and
specific functionality after long-term storage compared to
short-term results.
In summary, we have demonstrated that viability and
recovery values were high with all serum-free media used,
with lowest results for the HSA-based and the protein-free
medium with 5% DMSO. Functionality of PBMC also seemed
to be affected by these media. The cryopreservation efficiency
of two serum-free media, one based on BSA, the other even
protein-free and fully chemically defined with 10% DMSO,
was comparable to the FBS-medium during storage for a few
weeks and for several months. Cryopreservation in these
media resulted in high viability and recovery values after
short- and long-term storage of PBMC. Also the specific
functionality was maintained. The straightforward use of the
protein-free, fully chemically defined cryoprotocol enables
freezing of large quantities of cell samples for research
30 J.C. Schulz et al. / Journal of Immunological Methods 382 (2012) 24–31applications with high standardization and reproducibility.
Advantageously, it does not require complex cryoequipment,
e.g. programmed gradient-freezer etc., and it is easy to handle.
Even though the tested chemically defined cryomedium
(IBMT-Medium I) has not yet undergone the official cGMP
validations, all components are cGMP compatible making
clinical grade achievable.Acknowledgements
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